BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
January 22, 2024 06:45 ET
|
BioNTech SE
The pivotal Phase 3 trial with BNT323/DB-1303 follows positive Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced solid tumors...
Immunotherapy Targeting Mesothelin: A Comprehensive 2023 Pipeline Review
December 14, 2023 05:43 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Mesothelin-Targeted Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. A groundbreaking review of...
Folate Receptor Alpha Targeted Therapies - Exciting Advancements in Oncological R&D Revealed in Comprehensive Pipeline Review
December 14, 2023 05:28 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This pipeline review...
Anti-CD38 Antibody Pipeline Research Report 2023 Featuring Sorrento Therapeutics, I-MAB Biopharma, Takeda, Hangzhou Sumgen Biotech, Wuhan YZY Biopharma, and Biomunex Pharmaceuticals
November 22, 2023 08:38 ET
|
Research and Markets
Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Anti-CD38 antibody - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
Medicovestor, Inc announces the completion of an oversubscribed Seed Financing round to advance its novel Antibody Drug-Conjugate (ADC) platforms
November 20, 2023 10:00 ET
|
Medicovestor Inc
Medicovestor excels in oversubscribed Seed funding for its novel Anti-Drug Conjugate (ADC) platforms, gearing up for Series A in H1 2024.
Global Antibody Drug Conjugate (ADC) Competitive Landscape Report 2023: Company Analysis, Therapeutic Assessment, Pipeline Assessment, Inactive Drugs Assessment, Unmet Needs
November 17, 2023 08:13 ET
|
Research and Markets
Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...
Global CD19 Antibody Market Projected to Exceed $10 Billion by 2028, Driven by Promising Pipeline of Therapies
November 09, 2023 05:58 ET
|
Research and Markets
Dublin, Nov. 09, 2023 (GLOBE NEWSWIRE) -- The "Global CD19 Antibody Market & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The global CD19...
Global CD19 Antibody Market Set to Surpass $10 Billion by 2028: A Revolutionary Era in Immunotherapy
November 03, 2023 07:43 ET
|
Research and Markets
Dublin, Nov. 03, 2023 (GLOBE NEWSWIRE) -- The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The global CD19 Antibody...
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023 16:05 ET
|
Prelude Therapeutics, Inc.; AbCellera
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Global Antibody Drug Conjugates Market Poised to Reach $19.8 Billion by 2028, Fueled by Increasing Cancer Prevalence and Clinical Advancements
October 26, 2023 07:33 ET
|
Research and Markets
Dublin, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The "Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type...